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Abstract
Purpose For poorly understood reasons, invasive cervical
cancer (ICC) incidence and mortality rates are higher in
women of African descent. Oncogenic human papilloma-
virus (HPV) genotypes distribution may vary between
European American (EA) and African-American (AA)
women and may contribute to differences in ICC incidence.
The current study aimed at disentangling differences in
HPV distribution among AA and EA women.
Methods Five-hundred and seventy-two women were
enrolled at the time of colposcopic evaluation following an
abnormal liquid-based cytology screen. HPV infections
were detected using HPV linear array, and chi-squared tests
and linear regression models were used to compare HPV
genotypes across racial/ethnic groups by CIN status.
Results Of the 572 participants, 494 (86 %) had detectable
HPV; 245 (43 %) had no CIN lesion, 239 (42 %) had CIN1,
and 88 (15 %) had CIN2/3. Seventy-three percent of all
women were infected with multiple HPV genotypes. After
adjusting for race, age, parity, income, oral contraception use,
and current smoking, AAs were two times less likely to harbor
HPV 16/18 (OR 0.48, 95 % CI 0.21–0.94, p = 0.03) when all
women were considered. This association remained unchan-
ged when only women with CIN2/3 lesions were examined
(OR 0.22, 95 % CI 0.05–0.95, p = 0.04). The most frequent
high-risk HPV genotypes detected among EAs were 16, 18,
56, 39, and 66, while HPV genotypes 33, 35, 45, 58, and 68
were the most frequent ones detected in AAs.
Conclusions Our data suggest that while HPV 16/18 are
the most common genotypes among EA women with CIN,
AAs may harbor different genotypes.
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Introduction
In 2009, there were an estimated 34,788 new cases of
human papillomavirus (HPV)-associated cancers in the
USA overall, of which 61 % were among women (21,342)
and 39 % among men (13,446) [1]. Invasive cancer of the
uterine cervix (ICC) accounted for an estimated 12,340
cases in 2013 and continues to be the most common HPV-
associated cancer in women (53.4 %), followed by cancer
of the anus (16 %), vulva (15 %), oropharynx (12 %), and
vagina (3 %) [1]. However, the incidence of ICC is not
evenly distributed among racial/ethnic groups with Afri-
can-American (AA) and Hispanics affected disproportion-
ally higher than European American (EA) women [2].
Liquid-based cytology screening rates, whether self-
reported or estimated from insurance claims data, are
comparable among AAs and Hispanics compared with EAs
and fail to explain the racial/ethnic disparity [3–5].
Although AAs and Hispanics have lower incidence rates
for the more common cancer sites, they have the highest
incidence of ICC of any ethnic group in the USA. Cur-
rently, low-grade squamous intraepithelial lesions (LSILs)
and atypical squamous cells of undetermined significance
(ASCUS) cases are classified in ‘high-risk’ HPV-positive
or HPV-negative groups. Although the general consensus is
that HR-HPV genotypes 16 and 18 causes 70 % of ICC
cases and 50 % of CIN2–3, HPV-genotype distribution of
high-risk HPV types may vary by age [6], race/ethnicity
[7–9], which is also linked to socioeconomic status [10],
and geographic region [11–15]. Thus far, two studies in the
USA have described CIN2? lesions in ethnically diverse
populations [7, 10]; however, neither study described the
HPV distribution in the spectrum of all women with
abnormal cytology-based findings, reporting for colpos-
copy. In this report, we describe HPV genotypes associated
with CIN1–3 in a multiethnic cohort of women visiting
colposcopy clinics following a cervical abnormality.
Methods
Study participants were recruited from all 10 Duke Uni-
versity and Duke Primary Care (DPC) clinics in Durham
County, North Carolina, during 2010–2012. All clinics
used the same study protocol and the Duke University
Pathology Laboratory for cytology and histological evalu-
ation. All study participants were initially screened for
cervical abnormalities with the Thin-Prep liquid-based
cytology test (Cytyc). Inclusion criteria were, a visit to
one of 10 colposcopy clinic following an abnormal Pap
test, of at least LSIL, age 18 years or older, and English or
Spanish speaking. Questionnaires were written in English,
and a Spanish-speaking coordinator assisted and inter-
preted the content to Spanish-speaking study participants.
Also, both self- and interviewer-administered instruments
were identical in content. Women who did not intend to
receive follow-up care in one of the 10 DPC clinics or
moved out of the area for other reasons were excluded. Of
the 1,657 women with cytological abnormalities approa-
ched in the colposcopy clinic, 1,303 were enrolled, a
response rate of 79 %. These analyses are restricted to the
first 572 in whom data on race/ethnic, HPV infection, and
CIN status were available. Participants with detected HPV
genotypes were comparable to those of the entire cohort
not included in this analysis with respect to age (p = 0.83),
HPV infection (p = 0.87), yearly income (p = 0.36),
marital status (p = 0.44), cigarette smoking (p = 0.62),
and prior HPV vaccination (p = 0.57). This study was
approved by Duke University School of Medicine Institu-
tional Review Board, and all study participants signed an
informed consent explaining the nature of the study.
Data collection
A standardized questionnaire that was either self- or
interviewer-administered solicited information and inclu-
ded CIN and ICC progression risk factor data: age, race,
marital status, parity, yearly income, cigarette smoking,
oral contraceptive use, dietary, and sexual habits. Age and
yearly income were treated as continuous variables; race/
ethnicity was categorized as AA, EA, Hispanic, and other;
marital status into never married, married, widowed, living
with partner, divorced/separated, and other; parity into
nulliparity, one, two, three, and four, or more births; HPV-
DNA status, current smoking, oral contraceptive use, and
previous HPV vaccination into yes or no categories.
Additional information on pathological findings, as well as
lesion morphology (size and location), was abstracted from
the medical records.
Specimens
At the enrollment visit, the colposcopist co-investigator or
designee obtained a cervical specimen using a plastic
spatula and cytobrush and suspended it in the Thin-Prep
specimen vial containing a proprietary media with at least
50 % methanol (Cytyc, Malborough, MA, USA). Col-
poscopy-directed biopsies were also obtained from the
lesions. All specimens were tested for adequacy (KG)
using the 2002 ASCCP guidelines. The specimens were
stored at 4 C prior to HPV testing.
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Ascertainment of CIN
To ascertain the presence of CIN, the biopsies underwent
pathologic review. The hemotoxylin-and-eosin-stained
slides of individuals with cytological abnormalities were
read by the study pathologist (RB) laboratory.
HPV genotyping
Testing for 37 HPV-DNA subtypes was performed by Dr.
Gravitt’s laboratory at Johns Hopkins University, as pre-
viously described [16]. Briefly, HPV genotyping was per-
formed using HPV linear array (Roche Diagnostics) [17,
18]; HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, and 68 were considered high-risk or oncogenic
genotypes, whereas HPV 6, 11, 26, 40, 42, 53, 55, 61, 62,
69, 70, 72, 73, 81, 82, 83, and 84 were considered low-risk
(LR) HPV types [19, 20]. The seven beta-globin negative
samples were excluded from the analyses.
Statistical analysis
Women were classified as having either single or multiple
infections. Of the first 691 women for whom HPV geno-
typing has been completed, 572 also had covariate data
including race/ethnicity and age. Pearson’s chi-squared and
Fisher’s exact tests were used to compare women with no
evidence of CIN and those with CIN (CIN1, CIN2, and
CIN3). We computed the proportion of single and multiple
HPV infections and grouped them according to potential
oncogenicity [19, 20] by CIN lesion based on the Bethesda
criteria [21]. Analyses were repeated in EAs and in AAs,
and the prevalence of oncogenic HPV types, by race/eth-
nicity, was estimated. Associations between HPV 16/18
and race/ethnicity, adjusted for potential confounding by
age, race, parity, oral contraceptive use, current smoking,
and HPV vaccine status were examined using logistic
regression models. Statistical analyses were conducted
using SAS 9.2 (SAS Institute, Cary, NC).
Results
Of 572 participants, 494 (72 %) were HPV-positive; 245
(43 %) had no visible CIN, 239 (42 %) had CIN1, and 88
(15 %) had CIN2/3 (Table 1). Lower income women were
more likely to have histological evidence of CIN regardless
of grade, than higher income women (p \ 0.0001). Most
women with CIN1 (70 %) and CIN2 (61 %) were younger
(aged 20–29 years), whereas those with CIN3 were
30 years or older (p \ 0.0001). Those with CIN were more
likely to be infected with at least one of the 31 HPV
genotypes detected, which included low-risk types
(p = 0.06), and to be unmarried (p = 0.001). Only 73
(13 %) study participants reported being vaccinated against
HPV, and most (63 %) completed the vaccine doses
between the ages of 18–29 years old (p = 0.08). Most
(92 %) women with CIN reported having their sexual
intercourse at age 16 years or younger. Seventy-three
percent of women with CIN reported being current ciga-
rette smokers, compared with 15 % of women without
visible CIN lesions (p = 0.25).
HPV infection was found in 83 % of women without
CIN, and 88 and 94 % in those with CIN1 and CIN2?,
respectively. Most (73 %) women harbored multiple HPV
genotypes (Table 2). There were n = 7 beta-globin negative
samples, which were excluded from the analysis. Only five
women were HIV-positive and were also excluded from
analyses. In women with no CIN, the most common HPV
genotypes in single infections were 16, 35, 51, and 52,
whereas in multiple infections 51, 52, 56, 59, and 66 were
most commonly found. In CIN1, HPV genotypes 16, 31, 39,
51, 52, and 66 were the most frequent, whereas in CIN2/3
HPV 16, 18 (the latter found in multiple but not in single
infections), 31, 33, 35, 51 and 52 (in single infections) and
39 and 52 (in multiple infections) were the most common. In
CIN3 lesions, the prevalence of HPV genotype 16 was 36 %,
followed by 31 (13 %), 33 (9 %), 35 (9 %), 51 (9 %), and 52
(9 %) in single infections, and HPV 16, 52, 39, 18, 35, 45,
59, and 66 in multiple infections (Table 2).
Table 3 shows the distribution and odds ratios of
oncogenic HPV genotypes by race/ethnicity among all
participants who reported to the colposcopy clinic,
regardless of CIN status. AAs were two times less likely to
harbor high-risk HPV genotypes 16/18 compared with EAs
(OR 0.59, 95 % CI 0.37–0.95, p = 0.03). Adjusting for
age, race, income, parity, oral contraceptive use, and cur-
rent smoking did not materially change these associations
(OR 0.48, 95 % CI 0.21–0.94), p = 0.03) (Table 3).
Conversely, AA women with no evidence of CIN lesions
were more likely to be infected with high-risk HPV types
45, 33, 58, 35, and 68 (OR 3.45 95 % CI 1.23–9.68,
p = 0.01); an association that persisted in AA women with
CIN1 (OR 4.78 95 % CI 1.75–13.03, p = 0.002), but not in
those with CIN2/3 lesions (OR 1.22 95 % CI 0.32–4.61,
p = 0.76) (Table 4). We excluded from analyses women
who reported being vaccinated against HPV; median age at
vaccination was 21 years.
Discussion
Our key finding was that among women undergoing col-
poscopic evaluation following cytological abnormalities at
enrollment, infection with HPV 16 and 18 that are included
in bivalent and quadrivalent vaccine regimens was the most
Cancer Causes Control (2014) 25:1055–1062 1057
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commonly found in EA women. AA women were two
times less likely to be infected with HPV 16 and 18. This
race/ethnic difference persisted when comparisons was
restricted to women with histologically confirmed CIN1
and CIN2/3. Racial/ethnic differences have been recently
reported among women with advanced lesions (CIN2 or
worse) [7, 10]. To our knowledge, this is the first evidence
for racial/ethnic differences in the prevalence of HPV 16
and 18 infections among a large group of women with
cytological abnormalities, before treatment decisions are
made. We also found that genotypes most prevalent in AA
women were HPV 45, 33, 58, 35, and 68. While most
Table 1 Sociodemographic
characteristics of 572 study
participants
Numbers do not necessarily



















Age in years \0.0001
\20 (n = 9) 2 (1) 4 (2) 2 (3) 1 (3)
20–29 (n = 330) 114 (47) 167 (70) 35 (61) 14 (45)
29–40 (n = 129) 63 (26) 40 (17) 16 (28) 10 (32)
[40 (n = 103) 65 (26) 28 (12) 4 (7) 6 (19)
Yearly income U$S in
thousands




127 (52) 112 (47) 31 (54) 10 (32)
European American
(n = 292)
118 (48) 127 (53) 26 (46) 21 (68)
Marital status 0.001
Never married (n = 231) 83 (46) 120 (62) 21 (52) 7 (27)
Married (n = 78) 47 (26) 21 (11) 6 (15) 4 (15)
Widowed (n = 6) 4 (2) 1 (1) 0 (0) 1 (4)
Living with partner
(n = 41)
11 (6) 20 (10) 5 (13) 5 (19)
Divorced/separated
(n = 71)
32 (18) 25 (13) 6 (15) 8 (31)
Other (n = 12) 2 (1) 7 (3) 2 (5) 1 (4)
HPV 0.06
Any (n = 494) 202 (83) 210 (88) 53 (93) 29 (94)
None (n = 78) 43 (17) 29 (12) 4 (7) 2 (6)
Current smoke 0.25
Yes (n = 82) 28 (15) 36 (19) 10 (24) 8 (30)
No (n = 362) 153 (85) 158 (81) 32 (76) 19 (70)
Oral contraceptive use 0.60
Yes (n = 325) 136 (78) 145 (79) 28 (76) 16 (67)
No (n = 95) 39 (22) 39 (21) 9 (24) 8 (33)
Parity (live births) 0.24
Zero (n = 228) 97 (54) 106 (55) 18 (44) 7 (29)
One (n = 102) 46 (26) 41 (21) 8 (20) 7 (29)
Two (n = 68) 24 (13) 30 (15) 9 (22) 5 (21)
Three (n = 33) 9 (5) 15 (7) 5 (12) 4 (17)
Four or more (n = 6) 3 (2) 1 (1) 1 (2) 1 (4)
HPV vaccination 0.08
No (n = 293) 126 (82) 118 (75) 31 (91) 18 (86)
Yes age \18 years (n = 9) 7 (4) 1 (1) 1 (3) 0 (0)
Age 18–29 years (n = 63) 20 (13) 38 (24) 2 (6) 3 (14)
Age [29 (n = 1) 1 (1) 0 (0) 0 (0) 0 (0)
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women harbored at least one HPV type, co-infections were
also common. Therefore, while the singular importance of
HR-HPV 45, 33, 58, 35, and 68, as well as co-infections
with multiple HPV types, is still unclear, together these
findings suggest that in cases where triage decisions are
made based on infection with oncogenic HPV types 16 and
18, AAs may not receive follow-up care with comparable
frequency, if they harbor other genotypes.
Several global studies have reported variability in the
prevalence of HPV genotypes associated with cervical
lesions by geographic region and race/ethnicity, with
obvious potential implications for vaccine development
[11–13]. Few studies, however, have examined the preva-
lence in the USA in women predominantly with CIN1 and
ASCUS, where triage decisions are made. The current
findings are consistent with a recent report demonstrating
that HPV 16/18 infections are not common in high-grade
cervical lesions among AA and Hispanic women who were
not previously immunized against HPV [7, 10]. In fact, this
patient population is more likely to harbor HPV genotypes
other than 16/18. Niccolai et al. [10] found that a higher
degree of poverty is a strong predictor of lower HPV 16
Table 2 Distribution of HPV
types in CIN1, CIN2, and CIN3
in n = 494 participants
HPV genotypes in
ALL (n = 494)
No lesion
n = 202 (41 %)
CIN1
n = 210 (42 %)
CIN2/3














16 11 (16) 8 (5) 7 (10) 17 (9) 8 (36) 18 (16)
18 3 (4) 8 (5) 4 (5) 9 (5) – (0) 11 (9)
31 5 (7) 8 (5) 8 (11) 15 (8) 3 (13) 6 (5)
33 – (0) 5 (3) 1 (1) 4 (2) 2 (9) 4 (3)
35 11 (16) 5 (3) 2 (3) 7 (4) 2 (9) 8 (7)
39 – (0) 11 (7) 7 (9) 24 (13) – (0) 9 (10)
45 3 (4) 6 (4) 2 (3) 1 (0.5) – (0) 8 (7)
51 11 (16) 19 (12) 9 (12) 20 (10) 2 (9) 7 (6)
52 9 (12) 17 (11) 13 (18) 18 (9) 2 (9) 12 (11)
56 3 (4) 16 (10) 3 (4) 14 (7) 1 (4) 4 (3)
58 4 (6) 8 (5) 5 (7) 12 (6) 1 (4) 4 (3)
59 4 (6) 18 (12) 3 (4) 9 (5) 1 (4) 8 (7)
66 4 (6) 18 (12) 5 (7) 30 (16) – (0) 8 (7)
68 2 (3) 6 (4) 4 (5) 10 (5) – (0) 5 (4)
n = 31 n = 179 n = 21 n = 195 n = 5 n = 95
Other low-risk HPV type
26 2 (6) 4 (2) – (0) – (0) – (0) – (0)
53 9 (29) 16 (9) 8 (38) 13 (6) 1 (20) 4 (4)
70 5 (16) 6 (3) 2 (9) 7 (4) 1 (20) 4 (4)
73 1 (3) 7 (4) 1 (5) 3 (1) – (0) 3 (3)
82 – (0) 3 (2) 1 (5) 6 (3) – (0) – (0)
6 2 (6) 60 (33) 1 (5) 80 (41) – (0) 42 (44)
11 – (0) – (0) – (0) – (0) – (0) 1 (1)
40 1 (3) 2 (1) – (0) 3 (1) – (0) 2 (2)
42 1 (3) 11 (6) – (0) 11 (5) – (0) 5 (5)
55 2 (6) 8 (4) – (0) 6 (3) – (0) 3 (3)
61 1 (3) 12 (7) 1 (5) 13 (6) 1 (20) 8 (8)
62 2 (6) 12 (7) 4 (19) 24 (12) 1 (20) 11 (11)
69 – (0) – (0) – (0) – (0) – (0) 2 (2)
72 2 (6) 5 (3) 1 (5) 4 (2) – (0) 1 (1)
81 1 (3) 14 (8) – (0) 6 (3) 1 (20) 3 (3)
83 – (0) 6 (3) 1 (5) 6 (3) – (0) 4 (4)
84 2 (6) 13 (7) 1 (5) 13 (6) – (0) 2 (2)
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and 18 infections. Our present data showing that other
high-risk HPV genotypes, besides 16/18, may be associated
with CIN in AAs raise the possibility that racial/ethnic
disparity in ICC incidence could stem, in part from lack of
adequate follow-up among AA when HPV genotypes other
than 16 and 18 are detected.
Reasons why AA women are less likely to be infected
with HPV 16 and 18 are not known. One possibility is that
women of European descent are more susceptible to per-
sistent infection with HR-HPV 16/18 genotypes. Alterna-
tively, AA women may have lower exposure to HR-HPV
16/18 genotypes, or maybe more resistant to infection with
16/18, and possibly be carriers of other HR-HPV genotypes
that would increase susceptibility to developing high-grade
lesions and subsequently, ICC. Another possibility could
be a differential ability to clear the HPV infection among
racial/ethnic groups and/or the presence of different vari-
ants of HPV 16 and 18 [22]. We also cannot exclude the
possibility that our findings were by chance alone. None-
theless, both our findings and those of others [7] suggest
that the distribution of HPV genotypes in high-grade CIN
lesions in AA women in the USA is similar to that found in
Africa and South America, but differ from those observed
in EA women [15]. Larger US studies are needed to con-
firm and explain this racial/ethnic difference.
Seventy-three percent of all women infected with HPV
harbored multiple HPV genotypes, supporting previous
evidence [12–14] that the risk for CIN2? is higher in women
with multiple HPV infections [4]. Even though these find-
ings are consistent with those of others [5, 9], it is not yet
known how co-infections may lead to worse cervical disease
prognosis. Current knowledge suggests that each cervical
lesion is caused by a single HPV genotype [23]. It is possible
that a combination of factors including a compromised
immune system overloaded with multiple infections could
increase the field of injury, leading to chronic inflammation
and subsequent lesion progression. Alternatively, a genetic
predisposition or an epigenetic alteration [24, 25] may
prompt susceptibility to multiple infections.
Approximately 90 % of cervical HPV infections are
cleared within 2 years by the host immune system. How-
ever, persistent infection with high-risk HPV genotypes
Table 3 ORs and 95 % CI for
the associations between HR-
HPV and abnormal PAP smears
among AA and EA women
Bold indicates statistically
significant associations
a Adjusted for age, smoking,
parity, oral contraceptive, and
income (vaccinated women
were excluded from the
analysis)
b Referents were EAs













16–18 38 (36) 68 (64) 0.59 (0.37–0.95), 0.03 0.48 (0.21–0.94), 0.03
31 25 (52) 23 (48) 1.19 (0.63–2.34), 0.59 1.03 (0.43–2.47), 0.93
33 12 (67) 6 (33) 1.47 (0.51–4.19), 0.47 0.93 (0.24–3.64), 0.91
35 27 (71) 11 (29) 3.34 (1.43–8.07), 0.006 2.10 (0.70–6.27), 0.18
39 23 (43) 31 (57) 0.77 (0.39–1.49), 0.43 0.69 (0.26–1.83), 0.46
45 14 (58) 10 (42) 1.47 (0.59–3.67), 0.40 1.58 (0.44–5.67), 0.48
51 32 (48) 35 (52) 0.96 (0.54–1.71), 0.90 1.90 (0.81–4.48), 0.14
52 44 (54) 37 (46) 1.63 (0.94–2.80), 0.08 1.36 (0.63–2.91), 0.43
56 18 (42) 25 (58) 0.74 (0.36–1.52), 0.41 0.85 (0.32–2.24), 0.73
58 27 (67) 13 (33) 1.77 (0.77–4.08), 0.18 2.01 (0.53–7.67), 0.30
59 19 (42) 26 (58) 1.10 (0.55–2.20), 0.79 2.75 (0.94–8.00), 0.06
66 31 (42) 43 (58) 0.82 (0.46–1.43), 0.48 0.74 (0.33–1.65), 0.46
68 20 (61) 13 (39) 2.00 (0.84–4.76), 0.11 3.76 (1.10–12.79), 0.03
Table 4 Odds ratiosa and 95 % CI for the associations between high-risk HPV genotypes and race by CIN lesion
African-American womenb No lesion
n = 202 (41 %)
CIN1
n = 210 (42 %)
CIN2/3
n = 82 (17 %)
High-risk HPV type ORs (95 % CI), p value ORs (95 % CI), p value ORs (95 % CI), p value
16/18 0.59 (0.18–1.90), 0.38 0.54 (0.17–1.67), 0.28 0.22 (0.05–0.95), 0.04
45/33/58/35/68 3.45 (1.23–9.68), 0.01 4.78 (1.75–13.03), <0.01 1.22 (0.32–4.61), 0.76
31/39/51/52/56/59/66 1.46 (0.71–2.99), 0.29 0.69 (0.31–1.51), 0.35 1.63 (0.42–6.28), 0.47
Bold indicates statistically significant associations
a Adjusted for age, oral contraceptive use, parity, and current smoking (vaccinated women were excluded from the analysis)
b Referents were EA women
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predicts progression from HPV infection to high-grade
cervical intraepithelial lesions (CIN2/3) and to ICC. It is
possible that multiple infections with oncogenic HPV
genotypes may influence the risk of CIN2?; however, co-
infections were equally common in AAs and EAs.
These findings should be interpreted in the context of the
study limitations. The study participants did not include a
sample size of Hispanic women large enough for analyses;
therefore, the distribution of HPV genotypes in this ethnic
group could not be determined. Future studies that include
Latino women are required to elucidate the relative
importance of high-risk HPV genotypes in this ethnic
group. The study was not powered to histologically con-
firmed CIN2 and CIN3 lesions, and hence, CIN2 and CIN3
were combined, which while increasing the statistical
power, makes discerning aspects of CIN2 not related to
ICC difficult. However, CIN2/3 is the point of treatment in
the USA, and the two CIN categories are sometimes dif-
ficult to distinguish. Two prior studies with a much larger
sample size of CIN2/3 cases reported similar racial dif-
ferences [7, 10]. Despite these limitations, our findings
support the idea that there may be race/ethnic differences
in the distribution of HPV subtypes, with implications for
both screening and progression to ICC.
In summary, we have examined HPV genotypes in all
women with abnormal cytological findings, including CIN1
and 2/3 in an ethnically diverse US population and found
high-risk HPV genotypes that vary by race/ethnicity, even
before triage decisions are made. While small sample limits
inference, the findings support the contention that there are
racial/ethnic differences in the distribution of oncogenic
HPV genotypes among women with and without CIN that
require exploration in relation to progression to ICC. Larger
studies are needed to confirm this evidence and to help guide
cervical cancer risk stratification guidelines.
Acknowledgments We are grateful to Zhiqing Huang, Carole
Grenier, Brittany Price, Yvette Lacobie, Aileen Deeds, Francine
Overcash, Erin Erginer, Cara Davis, Allison Barratt, Amy Cantor,
Paul Whitaker and Alex Reaves for excellent technical support. This
paper was supported in part by grants from the National Institutes of
Health R01CA142983, and R01CA142983-02S1.
Conflict of interest The authors declare no conflict of interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Jemal A, Simard EP, Dorell C et al (2013) Annual report to the
nation on the status of cancer, 1975–2009, featuring the burden
and trends in human papillomavirus (HPV)-associated cancers
and HPV vaccination coverage levels. J Natl Cancer Inst
105:175–201
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics 2013.
CA Cancer J Clin 63:11–30
3. Singh GK, Miller BA, Hankey BF, Edwards BK (2004) Persistent
area socioeconomic disparities in US incidence of cervical cancer,
mortality, state, and survival, 1975–2000. Cancer 101:1051–1057
4. Coughlin SS, King J, Richards TB, Ekwueme DU (2006) Cer-
vical cancer screening among women living in metropolitan areas
of the United States by individual-level and area-based measures
of socio-economic status, 2000 to 2002. Cancer Epidemiol Bio-
markers Prev 15:2154–2159
5. Simard EP, Fedewa S, Ma J, Siegel R, Jemal A (2012) Widening
socioeconomic disparities in cervical cancer mortality among
women in 26 states, 1993–1997. Cancer 118:5110–5116
6. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, MacKin-
non J, Giuliano A (2009) Incidence trends of invasive cervical
cancer in the United States by combined race and ethnicity.
Cancer Causes Control 20:1129–1138
7. Hariri S, Unger ER, Powell SE et al (2012) Human papilloma-
virus genotypes in high-grade cervical lesions in the United
States. J Infect Dis 206:1878–1886
8. Coutlee F, Ratnam S, Ramanakumar AV et al (2011) Distribution
of human papillomavirus genotypes in cervical intraepithelial
neoplasia and invasive cervical cancer in Canada. J Med Virol
83:1034–1041
9. Insinga RP, Liaw KL, Johnson LG, Madeleine MM (2008) A
systematic review of the prevalence and attribution of human
papillomavirus types among cervical, vaginal, and vulvar prec-
ancers and cancers in the United States. Cancer Epidemiol Bio-
markers Prev 17:1611–1622
10. Niccolai LM, Russ CR, Julian PJ et al (2013) Individual and
geographic disparities in human papillomavirus types 16/18 in
high-grade cervical lesions. Cancer. doi:10.1002/cncr.28038
11. Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus
type distribution in invasive cervical cancer and high-grade cer-
vical lesions: a meta-analysis update. Int J Cancer 121:621–632
12. Vidal AC, Murphy SK, Hernandez BY et al (2011) Distribution
of HPV genotypes in cervical intraepithelial lesions and cervical
cancer in Tanzanian women. Infect Agent Cancer 6:20
13. de Sanjose S, Quint WG, Alemany L et al (2010) Human pap-
illomavirus genotype attribution in invasive cervical cancer: a
retrospective cross-sectional worldwide study. Lancet Oncol
11:1048–1056
14. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM
(2011) Human papillomavirus type distribution in 30,848 inva-
sive cervical cancer worldwide: variation by geographical region,
histological type and year of publication. Int J Cancer
128:927–935
15. Guan P, Howell-Jones R, Li N et al (2012) Human papilloma-
virus types in 115,789 HPV-positive women: a meta-analysis
from cervical infection to cancer. Int J Cancer 131:2349–2359
16. Tobian AA, Serwadda D, Quinn TC et al (2009) Male circum-
cision for the prevention of HSV-2 and HPV infections and
syphilis. N Engl J Med 360:1298–1309
17. Gravitt PE, Peyton CL, Alessi TQ et al (2000) Improved ampli-
fication of genital human papilloma viruses. J Clin Microbiol
38:357–361
18. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM (1998) Geno-
typing of 27 human papillomavirus types by using L1 consensus
PCR products by a single-hybridization, reverse line blot detec-
tion method. J Clin Microbiol 36:3020–3027
19. Bosch FX, Manos MM, Munoz N et al (1995) Prevalence of
human papillomavirus in cervical cancer: a worldwide perspec-
tive. J Natl Cancer Inst 87:796–802
Cancer Causes Control (2014) 25:1055–1062 1061
123
20. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El
Ghissassi F, WHO International Agency for Research on Cancer
(2005) Carcinogenicity of human papilloma viruses. Lancet
Oncol 6:204
21. Apgar BS, Zoschnick L, Wright TC (1998) The 2001 Bethesda
system terminology. Am Fam Physician 68:10
22. Xi LF, Koutsky LA, Hildesheim A et al (2007) Risk for high-
grade cervical intraepithelial neoplasia associated with variants of
human papillomavirus types 16 and 18. Cancer Epidemiol Bio-
markers Prev 16:4–10
23. Quint W, Jenkins D, Molijn A et al (2012) One virus, one lesion-
individual components of CIN lesions contain a specific HPV
type. J Pathol 227:62–71
24. Nye M, Hoyo C, Huang Z et al (2013) Associations between
methylation of paternally expressed gene 3, cervical intraepi-
thelial neoplasia and invasive cervical cancer in Tanzania. PLoS
One 8:e56325
25. Vidal AC, Henry NM, Murphy SK et al (2013) PEG1/MEST and
IGF2 DNA methylation in CIN and in cervical cancer. Clin
Transl Oncol. doi:10.1007/s12094-013-1067-4
1062 Cancer Causes Control (2014) 25:1055–1062
123
